Key result
Risperidone use in an adolescent was associated with the development of neuroleptic malignant syndrome, highlighting the potential for this fatal complication even with atypical neuroleptics.
Why the study?
Does risperidone cause neuroleptic malignant syndrome in adolescents?
Case Report (n=1)
Does risperidone cause neuroleptic malignant syndrome in adolescents?
This case report highlights that atypical neuroleptics like risperidone can induce neuroleptic malignant syndrome even in young adolescent patients.
Neuroleptic malignant syndrome (NMS) is a potentially fatal complication of neuroleptic therapy, characterized by fever, rigidity, mental status changes, and autonomic instability. Although NMS was previously associated with the use of high-potency neuroleptics, cases have begun to emerge with atypical neuroleptics. This article presents a risperidone-induced case in the youngest patient to date, raising issues concerning our perceptions, the safety of newer neuroleptics, and treatment of NMS.
No takes yet. Share an insight, caveat, or question.
Robb et al. (2000) conducted a case report in Neuroleptic malignant syndrome (n=1). Risperidone was evaluated on Neuroleptic malignant syndrome. Risperidone use in an adolescent was associated with the development of neuroleptic malignant syndrome, highlighting the potential for this fatal complication even with atypical neuroleptics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: